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Background: Estimated cancer mortality statistics were published for the years 2011 and 2012 for the European
Union (EU) and its six more populous countries.
Patients and methods: Using logarithmic Poisson count data joinpoint models and the World Health Organization
mortality and population database, we estimated numbers of deaths and age-standardized (world) mortality rates
(ASRs) in 2013 from all cancers and selected cancers.
Results: The 2013 predicted number of cancer deaths in the EU is 1 314 296 (737 747 men and 576 489 women).
Between 2009 and 2013, all cancer ASRs are predicted to fall by 6% to 140.1/100 000 in men, and by 4% to 85.3/
100 000 in women. The ASRs per 100 000 are 6.6 men and 2.9 women for stomach, 16.7 men and 9.5 women for
intestines, 8.0 men and 5.5 women for pancreas, 37.1 men and 13.9 women for lung, 10.5 men for prostate, 14.6
women for breast, and 4.7 for uterine cancer, and 4.2 and 2.6 for leukaemia. Recent trends are favourable except for
pancreatic cancer and lung cancer in women.
Conclusions: Favourable trends will continue in 2013. Pancreatic cancer has become the fourth cause of cancer
death in both sexes, while in a few years lung cancer will likely become the ﬁrst cause of cancer mortality in women as
well, overtaking breast cancer.
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introduction
Estimates of current cancer mortality statistics, extrapolated
from ofﬁcial data of a few years earlier, have long been
available for the USA [1–3] and have been published for the
years 2011 and 2012 for the European Union (EU) as a total
and for its six more populous countries [4, 5], based on the
World Health Organization (WHO) mortality database [6].
Here, we provide corresponding ﬁgures for the year 2013
using the same methodology and the WHO study database
updated to July 2012. This report also focuses speciﬁcally on
colorectal cancer, presenting the number of deaths and rate
estimates separately for various age groups, and discussing
reasons for age- and sex-speciﬁc trends.
materials and methods
This work is an update to the previous articles on predicted
European cancer mortality and is based on similar
methods [4, 5].
Ofﬁcial death certiﬁcation data from stomach, intestines
(colon and rectum), pancreas, lung, breast, uterus (cervix
and corpus), prostate, leukemias and total cancer mortality
were obtained from the WHO database (WHOSIS) [6].
Figures were derived for the EU in the period 1970–2009
and up to the most recent available year for six European
countries: France (2010), Germany (2010), Italy (2009),
Poland (2010), Spain (2010) and the UK (2010). The EU
was deﬁned as the current 27 member states. Data for
Cyprus were not available. For the calculation of the EU
rates, when data were not available for a country, the nearest
available data were replicated (see supplementary Appendix
1, available at Annals of Oncology online). No interpolation
was made for missing data in individual countries.
During the calendar period considered, three different
Revisions of the International Classiﬁcation of Diseases (ICD)
were used. Cancer deaths were re-coded according to the Tenth
Revision of the ICD [7]. ICD-10 encoding of the studied
cancers was: stomach cancer (C16), intestinal (mainly colon
and rectum) cancer (C17–C21, C26), pancreas (C25), lung
(C33–C34), breast (C50), uterus (cervix and corpus) (C53–
C55), prostate (C61), leukemias (C91–C95) and total cancers
(C00–D48).
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Estimates of the resident population were obtained from the
same WHO database. France and the UK lacked population
data for 2009 and 2010, respectively, which were obtained from
Eurostat instead [8]. Population projection estimates for the
year 2013 were obtained from Eurostat.
We computed age-speciﬁc rates and numbers of deaths for
each 5-year age group (from 0–4 to 80+ years) and calendar
year. Age-standardized rates (ASRs), per 100 000 men and
women, were computed by the direct method, using the world
standard population [9]. Quinquennial all-ages standardized
(world population) mortality rates were also calculated, as well
as quinquennial and annual standardized mortality rates for
colorectal cancer for the all-ages, 35–64 and 65–79 age groups.
A logarithmic Poisson count data joinpoint model was ﬁtted
to 5-year age-speciﬁc numbers of deaths in order to identify
the most recent trend segment. The joinpoint model was set to
a maximum of six identiﬁable segments (ﬁve joinpoints) and
to have at least ﬁve data-points from the last available period
[10]. A linear regression was then carried out over the
identiﬁed trend segment in order to compute predicted age-
speciﬁc numbers of deaths, the corresponding 95% conﬁdence
intervals (CIs) and prediction intervals (PIs) [11]. Predicted
age-speciﬁc and ASRs (with 95% CI and PI) were computed
using the predicted population data.
results
Table 1 shows total numbers of predicted deaths and
standardized death rates for the analyzed neoplasms with 95%
PI and CI, in the EU as a whole in 2013 as well as comparison
data for 2009. Total predicted number of cancer deaths in the
EU in 2013 is 1 314 236 compared with 1 281 694 in 2009. Of
these, 737 747 are men and 576 489 women, against 718 478
men and 563 216 women recorded in 2009. These ﬁgures
correspond to total cancer death rates of 140.1/100 000 men
and 85.3/100 000 women in 2013 in the EU, marking a 6% fall
in men and a 4% fall in women since 2009. In men, lung
cancer was responsible for most cancer deaths (25%) with
nearly 187 000 predicted deaths giving a rate of 37.2/100 000
men in 2013, corresponding to a 6% fall since 2009. In women,
breast cancer accounted for the largest number of predicted
cancer deaths (88 886 deaths, 14.6/100 000 women, 15% of
total) in 2013, corresponding to a 7% fall in rates since 2009 in
the EU. Female lung cancer deaths come a very close second
with 82 640 deaths (14% of total) in 2013 with a rate of 13.9/
100 000 women, marking a 7% rise since 2009. Pancreatic
cancer also had unfavourable mortality rates (8/100 000 men
and 5.5/100 000 women) for 2013; these are higher than those
of 2009 (7.9/100 000 men and 5.3/100 000 women) even
though by a very small margin. Figure 1 includes bar-plots of
standardized death rates and deaths for 2009 and the predicted
rates and deaths for 2013 with 95% PIs for total cancer
mortality in the EU in men and women. Figure 2 shows
mortality rates in 2009 and 2013 in the EU men and women
for the individual cancer sites.
Figures 3 and 4 illustrate trends in age-standardized cancer
mortality rates for EU men and women in 5-year steps from
1970 to 2009 and the predicted rates for 2013 for all cancers
(Figure 3) and individual sites (Figure 4). Recent trends for the
examined cancer sites in the EU are favourable in both sexes
with few exceptions, conﬁrming the favourable trend in total
cancer mortality since the late 1980s’ in men and earlier in
women. The main drivers of these favourable trends in men
are lung cancer, which has been decreasing since mortality
peaked in the late 1980s and stomach cancer, which has been
decreasing for several decades. In women, the falling rates are
mainly inﬂuenced by decreases in breast, intestinal and
stomach cancer. Breast cancer mortality peaked in the 1990s
and has been falling since, while intestinal and stomach cancer
mortalities have been falling for the entire period. Pancreatic
cancer is the only cancer site with unfavourable trends in both
sexes and the only one in men. In women, lung cancer
mortality conﬁrms its rising trend.
Supplementary Figure S1, available at Annals of Oncology
online, illustrates age-standardized (world population) cancer
mortality rate trends for men and women in quinquennia from
1970–1974 to 2005–2009 and the predicted rates for 2013 for
cancers of the stomach, intestines, pancreas, lung, breast,
uterus, prostate and leukemias in the studied countries
and the EU.
Overall cancer mortality trends were favourable all round for
both sexes and reﬂected the differences between countries in
individual cancer sites. Male total cancer predicted rates
reﬂected those of lung cancer, Poland having the highest rate
(175.3/100 000 men), substantially higher than the EU value.
Female overall predicted rates were highest in Poland and the
UK (between 95 and 100/100 000 women), while the lowest
was in Spain (67.8/100 000 women).
A detailed description of trends for selected cancer sites is
given in supplementary Appendix 2, available at Annals of
Oncology online.
Further details on country-speciﬁc data can be found in
supplementary Tables S1–S6, available at Annals of Oncology
online, which give total numbers of predicted deaths and
standardized death rates for the analyzed neoplasms with 95%
PI and CI for men and women, in the six examined European
countries in 2013 as well as comparison data from the last
available year in each country.
Table 2 gives age-standardized intestinal cancer mortality
rates in the EU and the six most populous member countries,
for all-ages, the 35–64 and 65–79 year age groups in the
quinquennia 2000–2004 and 2005–2009, with percentage
differences, as well as the 2013 predicted rates. Poland and
Spain show an unfavourable situation compared with other EU
countries and the whole EU, with predicted rates (21.8/100 000
men, Poland all-ages and 18.6/100 000 men, Spain all-ages)
that are both higher than those in 2005–2009 in men and
higher than those of other European countries and the EU
(16.7/100 000 men). In women, Polish rates are still the
highest, but the projected rates for 2013 are lower than those of
2005–2009 in the all-ages (10.8/100 000 women) and 65–79
age groups (93.1/100 000 women). Conversely, Polish middle-
aged women have a slightly higher 2013 rate compared with
2005–2009. Despite Spanish women having low total predicted
colorectal cancer rates (9/100 000 women) compared with the
EU (9.5/100 000 women), the middle-aged women’s predicted
rate (11/100 000 women) is higher than that recorded for
2005–2009 (10.9/100 000 women), a pattern similar to that of
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Table 1. Number of predicted deaths and standardized mortality rates in the EU for the year 2013, with 95% prediction and conﬁdence intervals, with comparison data from 2009.
Sex Cancer Number
of deaths
2009
Predicted
number of
deaths 2013
Lower
prediction
limit (95%)
Upper
prediction
limit (95%)
Lower
conﬁdence
limit (95%)
Upper
conﬁdence
limit (95%)
World
standardized
death rate 2009
Predicted world
standardized
death rate 2013
Lower
prediction
limit (95%)
Upper
prediction
limit (95%)
Lower
conﬁdence
limit (95%)
Upper
conﬁdence
limit (95%)
Men Stomach 36 574 34 767 34 190 35 344 34 383 35 151 7.46 6.59 6.48 6.70 6.52 6.66
Intestine (colon
and rectum)
87 818 91 751 90 566 92 937 90 860 92 643 17.30 16.71 16.46 16.97 16.51 16.92
Pancreas 36 713 40 069 39 493 40 645 39 642 40 496 7.85 8.01 7.89 8.13 7.91 8.11
Lung 18 3782 18 6970 18 4434 18 9506 18 5035 18 8904 39.57 37.18 36.66 37.70 36.76 37.60
Prostate 69 069 70 347 69 230 71 465 69 596 71 099 11.38 10.52 10.36 10.67 10.42 10.62
Leukaemias 22 025 22 653 22 080 23 226 22 234 23 072 4.64 4.19 4.02 4.36 4.10 4.28
All cancers
(malignant and benign)
718 478 737 747 730 074 745 419 731 736 743 757 148.37 140.06 138.48 141.65 138.79 141.34
Women Stomach 24 040 21 446 20 788 22 105 21 009 21 884 3.43 2.91 2.80 3.02 2.83 2.98
Intestine (colon and
rectum)
75 059 75 360 74 441 76 279 74 748 75 972 10.11 9.54 9.40 9.69 9.44 9.64
Pancreas 36 664 40 197 39 521 40 873 39 727 40 667 5.33 5.54 5.46 5.63 5.48 5.61
Lung 73 616 82 640 81 495 83 785 81 833 83 447 13.03 13.94 13.71 14.17 13.78 14.11
Breast 89 465 88 886 87 700 90 072 88 033 89 739 15.80 14.64 14.40 14.87 14.46 14.81
Uterus
(cervix and corpus)
27 596 27 446 26 913 27 979 27 017 27 876 5.00 4.69 4.57 4.81 4.60 4.79
Leukaemias 17 951 18 288 17 906 18 669 18 013 18 562 2.81 2.56 2.46 2.66 2.50 2.61
All cancers
(malignant and benign)
563 216 576 489 571 864 581 115 572 932 580 047 88.95 85.34 84.56 86.12 84.73 85.96
originalarticles
A
nnals
ofO
ncology

|M
alvezzietal.
Volum
e
24
|N
o.3
|M
arch
2013
Polish women, albeit with lower rates. All other countries
showed 2013 predicted rates smaller than those from 2005 to
2009. Figure 5 shows annual colorectal age-standardized death
rates in the EU per 100 000 population for all-ages, 35–64 and
65–79-year age groups from 1970 to 2009 and the resulting
joinpoint regression models for men and women, in addition
to the predicted rates for 2013 with 95% PIs. EU colorectal
cancer mortality trends should remain favourable even though
the truncated 35–64 age group trend appears less favourable
than for the other age groups.
discussion
The predicted number of deaths from cancer in the EU in the
year 2013 is 1 314 296 (737 747 men and 576 489 women),
slightly higher than the one in 2009. This slight increase in
deaths is due to population ageing. Between 2009 and 2013,
the age-adjusted mortality rates from all cancers are predicted
to fall by 6% in men and 4% in women, thus continuing the
favourable trends observed since the late 1980s in men and
since earlier in women [12]. Male all-cancer mortality rates are
Figure 1. Bar-plots of standardized death rates per 100 000 population and certiﬁed deaths for the year 2009 (dark grey) and the predicted rates and
number of deaths for 2013 with 95% PIs (light grey) for total cancer mortality in the EU in men and women.
Figure 2. Bar-plots of standardized death rates per 100 000 population for the year 2009 (dark grey) and the predicted rates for 2013 with 95% PIs (light
grey) for the EU in men and women in the studied cancer sites.
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about 65% higher than in women, and the recent greater fall in
men only marginally reduces the gap. The slower decrease in
female all-cancer mortality rates is largely due to the
differential trends between the two sexes in lung cancer
mortality, which is decreasing in men and increasing in
women. This mirrors the differential trends in smoking
prevalence observed in the past between the two sexes [13, 14].
The EU rates represent a weighted average of the rates in the
27 individual countries. The six countries considered, being the
most populous, have a great impact on the overall rate;
however, other EU countries may have an inﬂuence on the EU
rate. Among the six major countries, the lowest all-cancer
mortality rate in men in 2013 is in the UK, 10% lower than the
EU rate. The lowest rate in women is found in Spain, 20%
lower than that in the EU. Poland shows the highest rates in
both sexes, 25% higher than that in the EU in men and 13%
higher in women. Within the EU, there are large disparities in
cancer mortality, showing that there is still large room for
improvement. On a positive note, all-cancer mortality rates are
predicted to continue to decline in both sexes everywhere,
although the gap between Poland and the other countries does
not appear to decline.
The steady decline in stomach cancer mortality that started
several decades ago, in Europe as well as other areas of the
world, is still continuing [15]. This may reﬂect declines in the
prevalence of Helicobacter pylori infection, the main identiﬁed
risk factor for gastric cancer, but dietary habits, as well as the
fall of smoking in men, may also have played a role [16]. Still,
among the cancer sites considered, stomach is the one that
shows the largest variation between countries, with an over
threefold difference between the highest rates in Poland and
the lowest in the UK, suggesting that a large number of
stomach cancer deaths is still avoidable. An age-period-cohort
analysis of gastric cancer mortality rates in Europe [17] found
that an asymptote may have been reached for cohorts born
after 1940 in British and French men and in some Western
Figure 3. Age-standardized (world population) total cancer mortality trends in quinquennia from 1970–1974 to 2005–2009 and the predicted rates for
2013, for men (squares) and women (circles) in the EU.
original articles Annals of Oncology
 | Malvezzi et al. Volume 24 | No. 3 | March 2013
countries with very low rates in women. Conversely, cohort
effects continued to decline in countries with higher rates,
suggesting that in the future, rates will converge towards low
values.
Steady declines are also predicted in both sexes for
leukaemia, in women for breast and uterine cancers and in
men for prostate cancer, in the EU and in all six countries
considered, again conﬁrming the long-term favourable trends
for these sites [4, 5, 12]. Improvements in therapies, early
diagnosis and screening have most likely contributed to these
trends, albeit differently for each type of cancer.
The pancreas is the only major cancer site for which no
improvement in rates is predicted for either sex and, if
anything, a slight increase in rates is expected. Long-term
trends have shown increases in both sexes in the EU up to the
late 1980s, followed by a levelling off in rates up to the end of
the millennium, and possibly a slight increase in most recent
years [18]. Albeit diagnostic improvements may, at least in
part, account for the early rises, trends in more recent years are
difﬁcult to interpret. Cigarette smoking, the best recognized
risk factor, cannot account for recent trends in men, given that
lung cancer has been declining. Increases in obesity prevalence
may play a role in recent trends [18]. The pancreas is presently
the fourth cancer mortality site in the EU for both sexes,
having recently overtaken stomach cancer rates in both sexes
and uterine cancer rates in women.
The steady increase in lung cancer mortality in women in
the EU is expected to continue. Breast cancer rates are
expected to still be higher than lung cancer rates in women in
the EU in 2013, although the difference is small (14.6 versus
13.9/100 000 women). However, if the opposite trends in breast
and lung cancer mortality rates continue in the near future, in
2015 lung cancer may become the ﬁrst cause of cancer
mortality in women as well. This is already true in the UK and
in Poland, the two countries with the highest rates. A joinpoint
regression analysis [13] showed that while in Poland rates have
steadily increased, in the UK rates increased up to the late
1980s, subsequently declined up to the early 2000s, and
increased again in more recent years. An age-period-cohort
analysis [13] showed that in most countries, and in the EU as a
whole, cohort effects increased in women born between 1940
and 1970, followed by declines for more recent cohorts, albeit
based on small numbers. Conversely, in the UK, the highest
cohort effects were in women born in the 1920s, followed by
declines in risk, and then a plateau for women born in the
1940s, followed by ulterior declines in more recent generations.
It is, therefore, possible that the recent increase in lung cancer
mortality in UK women is transient, due to the additional
rises in smoking prevalence observed in the 1970s; the
favourable trends in younger women in the UK as well as in
several other European countries suggest that a levelling off
with rates around 15/100 000, and possibly some decrease in
Figure 4. Age-standardized (world population) EU male and female cancer mortalities in quinquennia from 1970–1974 to 2005–2009 and the predicted
rates for 2013. Men: stomach (squares), intestines (circles), pancreas (triangles), lung (crosses), prostate (xs) and leukemias (diamonds). Women: stomach
(squares), intestines (circles), pancreas (triangles), lung (crosses), breast (xs), uterus (diamonds) and leukemias (inverted triangles).
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Table 2. Standardized colorectal cancer mortality death rates for all-ages, 35–64 and 65–79 years in the quinquennia 2000–2004 and 2005–2009 with percentage difference and 2013 predicted all-ages rate in
the EU and selected countries.
All ages
standardized
death rate
2000–2004
All ages
standardized
death rate
2005–2009
% Difference
2000–2004
versus 2005–
2009
Predicted all-
ages
standardized
rate for 2013
35–64 years
standardized
death rate 2000–
2004
35–64 years
standardized
death rate 2005–
2009
% Difference
2000–2004
versus 2005–
2009
Predicted 35–64
years
standardized
rate for 2013
65–79 years
standardized
death rate 2000–
2004
65–79 years
standardized
death rate 2005–
2009
% Difference
2000–2004
versus 2005–
2009
Predicted 65–79
years
standardized
rate for 2013
Men
France 17.33 15.67 −9.62 13.95 17.49 16.25 −7.09 15.49 161.10 141.10 −12.41 113.95
Germany 18.92 16.23 −14.25 13.63 19.96 17.00 −14.82 13.60 177.95 152.16 −14.49 129.43
Italy 18.06 16.38 −9.31 15.29 19.04 16.80 −11.80 15.17 165.27 150.59 −8.89 142.18
Poland 20.17 20.70 2.62 21.75 22.55 22.02 −2.37 24.24 198.85 207.42 4.31 214.48
Spain 18.64 18.30 −1.80 18.64 19.59 19.38 −1.09 19.47 172.30 167.31 −2.90 174.67
UK 17.85 16.76 −6.09 16.31 18.98 17.30 −8.85 17.95 170.15 156.38 −8.09 142.56
European Union (27) 18.78 17.60 −6.25 16.71 20.16 18.74 −7.05 18.18 175.72 163.69 −6.84 152.28
Women
France 10.09 9.08 −10.02 8.13 10.95 10.08 −7.99 9.47 81.51 71.43 −12.37 58.46
Germany 11.98 10.03 −16.26 8.50 12.15 10.48 −13.79 8.70 101.26 82.86 −18.17 70.53
Italy 11.13 10.08 −9.36 9.25 13.15 11.85 −9.85 10.64 87.97 80.73 −8.23 73.16
Poland 12.01 11.34 −5.57 10.84 14.09 13.45 −4.53 13.50 107.51 100.42 −6.59 93.14
Spain 10.24 9.44 −7.82 9.02 12.10 10.87 −10.12 10.96 81.34 75.97 −6.60 67.97
UK 11.09 10.69 −3.67 9.82 11.99 11.77 −1.78 11.10 97.80 90.71 −7.26 75.53
European Union (27) 11.42 10.45 −8.50 9.54 12.80 11.80 −7.81 11.39 95.56 86.75 −9.21 73.84
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lung cancer mortality rates in EU women, could occur after
2020 [19].
Mortality from intestinal cancer (chieﬂy colorectal cancer) is
predicted to decline by 3.4% in men and 5.6% in women in the
EU between 2009 and 2013, again maintaining favourable
trends observed since the early 1990s in men and the early
1980s in women. However, while substantial declines are
predicted for all the six major countries in women, ranging
from −4% in the UK to −8.7% in Germany, patterns in men
are more heterogeneous. Declines around 8% are predicted in
France and Germany, around 4% in Italy, but only around 1%
in Spain and the UK, while a slight increase in rates (+1.4%) is
predicted for Poland. Although there were large differences in
intestinal cancer mortality rates in the early 1970s, converging
patterns have been observed across various areas of Europe
[20]. As a consequence, intestinal mortality rates in 2013 show
less variation across major European countries than other
cancer sites, particularly in women, where the lowest rate in
France is only 25% lower than the highest rate in Poland. A
more homogeneous lifestyle (including diet) across Europe
may explain the converging pattern in colorectal cancer rates.
Improvements in therapies and screening/early diagnosis have
had a favourable impact on mortality. It is, however, difﬁcult to
explain the different patterns between the two sexes in some,
but not all, countries. The earlier more favourable trends in
women may be attributed in part to more favourable dietary
and lifestyle habits in women, and in part to the introduction
of oral contraceptives and other exogenous female hormone
preparations in the 1950s and 1960s [21]. Following the early
stopping of the Women’s Health Initiative in 2002 [22]
(a randomized trial comparing combined hormone
replacement treatment (HRT) to placebo), because the overall
health risks exceeded the beneﬁts, falls in HRT use were
reported in the US as well as in several European countries
[23]. Falls in breast cancer incidence in some countries have
been related to these decreases in HRT use [23]. Given the
postulated protective effect of HRT on colorectal cancer, the
reduced HRT use should lead to a less favourable pattern in
colorectal cancer incidence in women. However, it may still be
too early to detect effects on mortality rates.
While until recently (up to 2009) younger age groups
appeared to have even more favourable trends [24], suggesting
further improvements in the overall rates in the future, the
predictions for the year 2013 do not support this observation
anymore. Given the uncertainties inherent in prediction
models, this should be considered with utmost care. If true,
however, this may suggest less favourable trends in the future.
On the other hand, organized colorectal cancer screening has
been introduced in several European countries relatively
recently, and it is generally not offered to younger age groups
[25]. Therefore, when the potential beneﬁts of screening start
to affect mortality, an effect is to be expected above a certain
age only.
In conclusion, cancer mortality prediction for the year 2013
conﬁrms the favourable trend in overall cancer mortality in the
EU, as well as in several major cancer sites, with the notable
exceptions of pancreatic cancer in both sexes, and lung cancer
in women, which seems set to become, within a few years, the
ﬁrst cause of cancer mortality in women as well, overtaking
breast cancer.
Figure 5. Annual age-standardized colorectal cancer death rates in the EU per 100 000 population for all-ages, 35–64 and 65–79 year age groups from 1970
to 2009 and the resulting joinpoint regression models. In addition to the predicted rates for the year 2013 with 95% prediction intervals. On the left, male
all-ages (squares), male 35–64 years (triangles), female all-ages (circles) and female 35–64 years (crosses). On the right, male 65–79 years (squares) and
female 65–79 years (circles).
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